|Dr. André Choulika||Co-Founder, Chairman & CEO||398.88k||N/A||1965|
|Dr. David J. D. Sourdive||Co-Founder, Exec. VP - Technical Operations and Director||304.99k||N/A||1967|
|Mr. Eric Dutang||Chief Financial Officer||N/A||N/A||1974|
|Ms. Elsy Boglioli||Chief Operating Officer||N/A||N/A||1982|
|Mr. Jean Charles Epinat||Chief Technological Officer||N/A||N/A||N/A|
Cellectis S.A., a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL). The company's products also comprise UCART123 for acute myeloid leukemia indications and blastic plasmacytoid dendritic cell neoplasm; UCARTCS1 for multiple myeloma (MM) indications; UCART22 for ALL; and UCART38 for T-ALL. In addition, it focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology. The company has strategic alliances with Pfizer Inc; Les Laboratoires Servier SAS; The University of Texas MD Anderson Cancer Center to research and develop novel cellular immunotherapies for patients suffering from various liquid tumors; and Cornell University to accelerate the development of a targeted immunotherapy for patients with acute myeloid leukemia, as well as a partnership agreement with the Wyss Institute for Biologically Inspired Engineering at Harvard University. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Cellectis S.A.’s ISS Governance QualityScore as of July 1, 2018 is 10. The pillar scores are Audit: 1; Board: 10; Shareholder Rights: 6; Compensation: 10.